Search

Your search keyword '"Simeone, Ester"' showing total 433 results
Start Over Author "Simeone, Ester"
433 results on '"Simeone, Ester"'

2. Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

Author

Modestino, Luca, Cristinziano, Leonardo, Trocchia, Marialuisa, Ventrici, Annagioia, Capone, Mariaelena, Madonna, Gabriele, Loffredo, Stefania, Ferrara, Anne Lise, Romanelli, Marilena, Simeone, Ester, Varricchi, Gilda, Rossi, Francesca Wanda, de Paulis, Amato, Marone, Gianni, Ascierto, Paolo Antonio, and Galdiero, Maria Rosaria

Published
2023
Full Text
View/download PDF

4. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Author

Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester, and Ascierto, Paolo A.

Published
2023
Full Text
View/download PDF

6. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

Author

Mallardo, Domenico, Simeone, Ester, Festino, Lucia, Tuffanelli, Marilena, Vanella, Vito, Trojaniello, Claudia, Vitale, Maria Grazia, Ottaviano, Margaret, Capone, Mariaelena, Madonna, Gabriele, Sparano, Francesca, Cioli, Eleonora, Scarpato, Luigi, Palla, Marco, Di Trolio, Rossella, Meinardi, Paolo, Caracò, Corrado, Ferrara, Gerardo, Muto, Paolo, Cavalcanti, Ernesta, and Ascierto, Paolo Antonio

Published
2023
Full Text
View/download PDF

7. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile

Author

Ascierto, Paolo A., Di Giacomo, Anna M., Chiarion Sileni, Vanna, Queirolo, Paola, Spagnolo, Francesco, De Galitiis, Federica, Cognetti, Francesco, Mandalà, Mario, Guidoboni, Massimo, Rinaldi, Gaetana, Depenni, Roberta, Consoli, Francesca, Troiani, Teresa, Guida, Michele, Marconcini, Riccardo, Ferrucci, Pier F., Strippoli, Sabino, Fava, Paolo, Merelli, Barbara, Simeone, Ester, Di Guardo, Lorenza, Giannarelli, Diana, Maio, Massimo, Quaglino, Pietro, and Del Vecchio, Michele

Published
2023
Full Text
View/download PDF

10. ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.

Author

Mallardo, Domenico, Fordellone, Mario, Ottaviano, Margaret, Marano, Giuseppina, Vitale, Maria Grazia, Mallardo, Mario, Capasso, Mariagrazia, De Cristofaro, Teresa, Capone, Mariaelena, Meinardi, Teresa, Paone, Miriam, Sabatelli, Patrizia, De Filippi, Rosaria, Cesano, Alessandra, Cavalcanti, Ernesta, Caracò, Corrado, Warren, Sarah, Budillon, Alfredo, Simeone, Ester, and Ascierto, Paolo Antonio

Abstract

We previously demonstrated that patients with metastatic unresectable stage IIIb–IV melanoma receiving cetirizine (a second-generation H1 antagonist antihistamine) premedication with immunotherapy had better outcomes than those not receiving cetirizine. In this retrospective study, we searched for a gene signature potentially predictive of the response to the addition of cetirizine to checkpoint inhibition (nivolumab or pembrolizumab with or without previous ipilimumab). Transcriptomic analysis showed that inducible T cell costimulator ligand (ICOSLG) expression directly correlated with the disease control rate (DCR) when detected with a loading value > 0.3. A multivariable logistic regression model showed a positive association between the DCR and ICOSLG expression for progression-free survival and overall survival. ICOSLG expression was associated with CD64, a specific marker of M1 macrophages, at baseline in the patient samples who received cetirizine concomitantly with checkpoint inhibitors, but this association was not present in subjects who had not received cetirizine. In conclusion, our results show that the clinical advantage of concomitant treatment with cetirizine during checkpoint inhibition in patients with malignant melanoma is associated with high ICOSLG expression, which could predict the response to immune checkpoint inhibitor blockade. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization

Author

Mallardo, Domenico, Simeone, Ester, Vanella, Vito, Vitale, Maria Grazia, Palla, Marco, Scarpato, Luigi, Paone, Miriam, De Cristofaro, Teresa, Borzillo, Valentina, Cortellini, Alessio, Sparano, Francesca, Pignata, Sandro, Fiore, Francesco, Caracò, Corrado, Maiolino, Piera, Petrillo, Antonella, Cavalcanti, Ernesta, Lastoria, Secondo, Muto, Paolo, Budillon, Alfredo, Warren, Sarah, and Ascierto, Paolo Antonio

Published
2022
Full Text
View/download PDF

12. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma

Author

Mallardo, Domenico, primary, Sparano, Francesca, additional, Vitale, Maria Grazia, additional, Trojaniello, Claudia, additional, Cioli, Eleonora, additional, Esposito, Assunta, additional, Festino, Lucia, additional, Mallardo, Mario, additional, Vanella, Vito, additional, Facchini, Bianca Arianna, additional, Filippi, Rosaria, additional, Meinardi, Paolo, additional, Ottaviano, Margaret, additional, Caracò, Corrado, additional, Simeone, Ester, additional, and Ascierto, Paolo Antonio, additional

Published
2024
Full Text
View/download PDF

13. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

Author

Simeone, Ester, Scognamiglio, Giosuè, Capone, Mariaelena, Giannarelli, Diana, Grimaldi, Antonio M., Mallardo, Domenico, Madonna, Gabriele, Curvietto, Marcello, Esposito, Assunta, Sandomenico, Fabio, Sabbatino, Francesco, Bayless, Nicholas L., Warren, Sarah, Ong, SuFey, Botti, Gerardo, Flaherty, Keith T., Ferrone, Soldano, and Ascierto, Paolo A.

Published
2021
Full Text
View/download PDF

14. 1247 Gene signature predict autoimmune toxicity in patients with metastatic melanoma

Author

Mallardo, Domenico, primary, Fordellone, Mario, additional, Bailey, Michael, additional, Tuffanelli, Marilena, additional, White, Andrew, additional, Simeone, Ester, additional, Festino, Lucia, additional, Vanella, Vito, additional, Trojaniello, Claudia, additional, Vitale, Maria Grazia, additional, Ottaviano, Margaret, additional, Sparano, Francesca, additional, Facchini, Bianca Arianna, additional, Cavalcanti, Ernesta, additional, Church, Sarah, additional, Caraco, Corrado, additional, Cesano, Alessandra, additional, Budillon, Alfredo, additional, Warren, Sarah, additional, Chiodini, Paolo, additional, and Ascierto, Paolo, additional

Published
2023
Full Text
View/download PDF

15. 579 Evaluation of cemiplimab treatment duration: clinical outcomes in advanced CSCC

Author

Mallardo, Domenico, primary, Sparano, Francesca, additional, Vitale, Maria Grazia, additional, Trojaniello, Claudia, additional, Cioli, Eleonora, additional, Esposito, Assunta, additional, Festino, Lucia, additional, Mallardo, Mario, additional, Vanella, Vito, additional, Cristofaro, Teresa De, additional, Facchini, Boanca Arianna, additional, Meinardi, Paolo, additional, Ottaviano, Margaret, additional, Caraco, Corrado, additional, Budillon, Alfredo, additional, Simeone, Ester, additional, and Ascierto, Paolo, additional

Published
2023
Full Text
View/download PDF

16. 41 CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy

Author

Mallardo, Domenico, primary, Fordellone, Mario, additional, White, Andrew, additional, Ottaviano, Margaret, additional, Sparano, Francesca, additional, Bailey, Michael, additional, Facchini, Bianca Arianna, additional, Ong, SuFey, additional, Maiolino, Piera, additional, Caraco, Corrado, additional, Church, Sarah, additional, Cavalcanti, Ernesta, additional, Warren, Sarah, additional, Budillon, Alfredo, additional, Cesano, Alessandra, additional, Simeone, Ester, additional, Chiodini, Paolo, additional, and Ascierto, Paolo, additional

Published
2023
Full Text
View/download PDF

17. 42 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a deep biomarker analysis

Author

Mallardo, Domenico, primary, Arpino, Sergio, additional, Vitale, Maria Grazia, additional, Minopoli, Anita, additional, Tuffanelli, Marilena, additional, Trojaniello, Claudia, additional, Mallardo, Mario, additional, D’angelo, Grazia, additional, Vanella, Vito, additional, Sparano, Francesca, additional, Cioli, Eleonora, additional, Alfano, Benedetta, additional, Festino, Lucia, additional, Budillon, Alfredo, additional, Simeone, Ester, additional, Caraco, Corrado, additional, Cavalcanti, Ernesta, additional, and Ascierto, Paolo, additional

Published
2023
Full Text
View/download PDF

18. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

Author

Pistillo, Maria Pia, Fontana, Vincenzo, Morabito, Anna, Dozin, Beatrice, Laurent, Stefania, Carosio, Roberta, Banelli, Barbara, Ferrero, Francesca, Spano, Laura, Tanda, Enrica, Ferrucci, Pier Francesco, Martinoli, Chiara, Cocorocchio, Emilia, Guida, Michele, Tommasi, Stefania, De Galitiis, Federica, Pagani, Elena, Antonini Cappellini, Gian Carlo, Marchetti, Paolo, Quaglino, Pietro, Fava, Paolo, Osella-Abate, Simona, Ascierto, Paolo Antonio, Capone, Mariaelena, Simeone, Ester, Romani, Massimo, Spagnolo, Francesco, Queirolo, Paola, and On behalf of the Italian Melanoma Intergroup (IMI)

Published
2019
Full Text
View/download PDF

19. CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Author

Mallardo, Domenico, primary, Fordellone, Mario, additional, White, Andrew, additional, Ottaviano, Margaret, additional, Sparano, Francesca, additional, Bailey, Michael, additional, Facchini, Arianna, additional, Ong, Sufey, additional, Maiolino, Piera, additional, Caracò, Corrado, additional, Church, Sarah, additional, Cavalcanti, Ernesta, additional, Warren, Sarah, additional, Budillon, Alfredo, additional, Cesano, Alessandra, additional, Simeone, Ester, additional, Chiodini, Paolo, additional, and Ascierto, Paolo A., additional

Published
2023
Full Text
View/download PDF

20. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Author

Coutzac, Clélia, Jouniaux, Jean-Mehdi, Paci, Angelo, Schmidt, Julien, Mallardo, Domenico, Seck, Atmane, Asvatourian, Vahe, Cassard, Lydie, Saulnier, Patrick, Lacroix, Ludovic, Woerther, Paul-Louis, Vozy, Aurore, Naigeon, Marie, Nebot-Bral, Laetitia, Desbois, Mélanie, Simeone, Ester, Mateus, Christine, Boselli, Lisa, Grivel, Jonathan, Soularue, Emilie, Lepage, Patricia, Carbonnel, Franck, Ascierto, Paolo Antonio, Robert, Caroline, and Chaput, Nathalie

Published
2020
Full Text
View/download PDF

22. Supplementary Table 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Methods from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 4 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Author

Weide, Benjamin, primary, Martens, Alexander, primary, Hassel, Jessica C., primary, Berking, Carola, primary, Postow, Michael A., primary, Bisschop, Kees, primary, Simeone, Ester, primary, Mangana, Johanna, primary, Schilling, Bastian, primary, Di Giacomo, Anna Maria, primary, Brenner, Nicole, primary, Kähler, Katharina, primary, Heinzerling, Lucie, primary, Gutzmer, Ralf, primary, Bender, Armin, primary, Gebhardt, Christoffer, primary, Romano, Emanuela, primary, Meier, Friedegund, primary, Martus, Peter, primary, Maio, Michele, primary, Blank, Christian, primary, Schadendorf, Dirk, primary, Dummer, Reinhard, primary, Ascierto, Paolo A., primary, Hospers, Geke, primary, Garbe, Claus, primary, and Wolchok, Jedd D., primary

Published
2023
Full Text
View/download PDF

27. Immunotherapy Assessment: A New Paradigm for Radiologists

Author

Granata, Vincenza, primary, Fusco, Roberta, additional, Setola, Sergio Venanzio, additional, Simonetti, Igino, additional, Picone, Carmine, additional, Simeone, Ester, additional, Festino, Lucia, additional, Vanella, Vito, additional, Vitale, Maria Grazia, additional, Montanino, Agnese, additional, Morabito, Alessandro, additional, Izzo, Francesco, additional, Ascierto, Paolo Antonio, additional, and Petrillo, Antonella, additional

Published
2023
Full Text
View/download PDF

33. 21 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a real life study

Author

Mallardo, Domenico, primary, Isgrò, Maria Antonietta, additional, Vanella, Vito, additional, Tuffanelli, Marilena, additional, Festino, Lucia, additional, Vitale, Maria Grazia, additional, D’angelo, Grazia, additional, Sparano, Francesca, additional, Mallardo, Mario, additional, Cioli, Eleonora, additional, Alfano, Benedetta, additional, Trojaniello, Claudia, additional, Budillon, Alfredo, additional, Simeone, Ester, additional, Caracò, Corrado, additional, Cavalcanti, Ernesta, additional, and Ascierto, Paolo, additional

Published
2022
Full Text
View/download PDF

36. Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients.

Author

Galati, Domenico, Zanotta, Serena, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Romanelli, Marilena, Simeone, Ester, Festino, Lucia, Sparano, Francesca, Azzaro, Rosa, De Filippi, Rosaria, Pinto, Antonio, Paulos, Chrystal M., and Ascierto, Paolo A.

Subjects
BRAF genes, PATIENT selection, NIVOLUMAB, T cells, BLOOD cells, MELANOMA, DISTRIBUTION (Probability theory)
Abstract

Background: Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients' outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. In addition, no robust and reproducible biomarkers have yet been validated to identify the correct selection of patients who will benefit from anti-PD-1 treatment avoiding unwanted side effects. However, the strength of CD26 expression on CD4+ T lymphocytes permits the characterization of three subtypes with variable degrees of responsiveness to tumors, suggesting that the presence of CD26-expressing T cells in patients might be a marker of responsiveness to PD-1-based therapies. Methods: The frequency distribution of peripheral blood CD26-expressing cells was investigated employing multi-parametric flow cytometry in 69 metastatic melanoma patients along with clinical characteristics and blood count parameters at baseline (W0) and compared to 20 age- and sex-matched healthy controls. Percentages of baseline CD4+CD26high T cells were correlated with the outcome after nivolumab treatment. In addition, the frequency of CD4+CD26high T cells at W0 was compared with those obtained after 12 weeks (W1) of therapy in a sub-cohort of 33 patients. Results: Circulating CD4+CD26high T cells were significantly reduced in melanoma patients compared to healthy subjects (p = 0.001). In addition, a significant association was observed between a low baseline percentage of CD4+CD26high T cells (< 7.3%) and clinical outcomes, measured as overall survival (p = 0.010) and progression-free survival (p = 0.014). Moreover, patients with clinical benefit from nivolumab therapy had significantly higher frequencies of circulating CD4+CD26high T cells than patients with non-clinical benefit (p = 0.004) at 12 months. Also, a higher pre-treatment proportion of circulating CD4+CD26high T cells was correlated with Disease Control Rate (p = 0.014) and best Overall Response Rate (p = 0.009) at 12 months. Interestingly, after 12 weeks (W1) of nivolumab treatment, percentages of CD4+CD26high T cells were significantly higher in comparison with the frequencies measured at W0 (p < 0.0001), aligning the cell counts with the ranges seen in the blood of healthy subjects. Conclusions: Our study firstly demonstrates that peripheral blood circulating CD4+CD26high T lymphocytes represent potential biomarkers whose perturbations are associated with reduced survival and worse clinical outcomes in melanoma patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Additional file 1 of Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization

Author

Mallardo, Domenico, Simeone, Ester, Vanella, Vito, Vitale, Maria Grazia, Palla, Marco, Scarpato, Luigi, Paone, Miriam, De Cristofaro, Teresa, Borzillo, Valentina, Cortellini, Alessio, Sparano, Francesca, Pignata, Sandro, Fiore, Francesco, Caracò, Corrado, Maiolino, Piera, Petrillo, Antonella, Cavalcanti, Ernesta, Lastoria, Secondo, Muto, Paolo, Budillon, Alfredo, Warren, Sarah, and Ascierto, Paolo Antonio

Abstract

Additional file 1. Supplementary table 1. Description of genes expressed either with cetirizine administration or without cetirizine in the overall population.

Published
2022
Full Text
View/download PDF

40. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents

Author

Turiello, Roberta, primary, Capone, Mariaelena, additional, Morretta, Elva, additional, Monti, Maria Chiara, additional, Madonna, Gabriele, additional, Azzaro, Rosa, additional, Del Gaudio, Pasquale, additional, Simeone, Ester, additional, Sorrentino, Antonio, additional, Ascierto, Paolo A, additional, and Morello, Silvana, additional

Published
2022
Full Text
View/download PDF

41. Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas

Author

Ottaviano, Margaret, primary, Giunta, Emilio Francesco, additional, Marandino, Laura, additional, Tortora, Marianna, additional, Attademo, Laura, additional, Bosso, Davide, additional, Cardalesi, Cinzia, additional, Fabbrocini, Antonietta, additional, Rosanova, Mario, additional, Silvestri, Antonia, additional, Montella, Liliana, additional, Tammaro, Pasquale, additional, Marra, Ester, additional, Trojaniello, Claudia, additional, Vitale, Maria Grazia, additional, Simeone, Ester, additional, Troiani, Teresa, additional, Daniele, Bruno, additional, and Ascierto, Paolo Antonio, additional

Published
2022
Full Text
View/download PDF

42. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma

Author

Ruggiero, Ciro Francesco, primary, Fattore, Luigi, additional, Terrenato, Irene, additional, Sperati, Francesca, additional, Salvati, Valentina, additional, Madonna, Gabriele, additional, Capone, Mariaelena, additional, Valenti, Fabio, additional, Di Martino, Simona, additional, Mandoj, Chiara, additional, Liguoro, Domenico, additional, Castaldo, Vittorio, additional, Cafaro, Giordana, additional, Simeone, Ester, additional, Vanella, Vito, additional, Russillo, Michelangelo, additional, Conti, Laura, additional, Cuda, Giovanni, additional, Giannarelli, Diana, additional, Ascierto, Paolo Antonio, additional, Mancini, Rita, additional, and Ciliberto, Gennaro, additional

Published
2022
Full Text
View/download PDF

43. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Author

Simeone, Ester, Gentilcore, Giusy, Giannarelli, Diana, Grimaldi, Antonio M., Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Palla, Marco, Cavalcanti, Ernesta, Sandomenico, Fabio, Petrillo, Antonella, Botti, Gerardo, Fulciniti, Franco, Palmieri, Giuseppe, Queirolo, Paola, Marchetti, Paolo, Ferraresi, Virginia, Rinaldi, Gaetana, Pistillo, Maria Pia, Ciliberto, Gennaro, Mozzillo, Nicola, and Ascierto, Paolo A.

Published
2014
Full Text
View/download PDF

44. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Author

Queirolo, Paola, Spagnolo, Francesco, Ascierto, Paolo Antonio, Simeone, Ester, Marchetti, Paolo, Scoppola, Alessandro, Del Vecchio, Michele, Di Guardo, Lorenza, Maio, Michele, Di Giacomo, Anna Maria, Antonuzzo, Andrea, Cognetti, Francesco, Ferraresi, Virginia, Ridolfi, Laura, Guidoboni, Massimo, Guida, Michele, Pigozzo, Jacopo, and Chiarion Sileni, Vanna

Published
2014
Full Text
View/download PDF

45. 24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome

Author

Mallardo, Domenico, primary, Vitale, Maria Grazia, additional, Giannarelli, Diana, additional, Trillò, Giusy, additional, Esposito, Assunta, additional, Capone, Mariaelena, additional, Isgrò, Maria Antonietta, additional, Madonna, Gabriele, additional, D’Angelo, Grazia, additional, Festino, Lucia, additional, Vanella, Vito, additional, Trojaniello, Claudia, additional, Manzoni, Alessandro, additional, White, Andrew, additional, Bailey, Michael, additional, Simeone, Ester, additional, Caracò, Corrado, additional, Maiolino, Piera, additional, Normanno, Nicola, additional, Warren, Sarah, additional, Cavalcanti, Ernesta, additional, and Ascierto, Paolo, additional

Published
2021
Full Text
View/download PDF

46. 308 Transcriptomic analysis of melanoma patients in adjuvant setting treated with anti PD1 therapy: real life study

Author

Mallardo, Domenico, primary, Trojaniello, Claudia, additional, Vitale, Maria Grazia, additional, d’angelo, grazia, additional, White, Andrew, additional, Capone, Mariaelena, additional, Sorrentino, Antonio, additional, Madonna, Gabriele, additional, Tuffanelli, Marilena, additional, Vanella, Vito, additional, Festino, Lucia, additional, Simeone, Ester, additional, Caracò, Corrado, additional, Normanno, Nicola, additional, Warren, Sarah, additional, and Ascierto, Paolo, additional

Published
2021
Full Text
View/download PDF

47. 934 Biological mechanisms in the different etiologies of Merkel cell carcinoma patients: polyomavirus or UV exposure

Author

Mallardo, Domenico, primary, Scognamiglio, Giosuè, additional, North, Khrystyna, additional, Capone, Mariaelena, additional, Bailey, Michael, additional, Scarpato, Luigi, additional, Church, Sarah, additional, Madonna, Gabriele, additional, Reeves, Jason, additional, Curvietto, Marcello, additional, Tuffanelli, Marilena, additional, d’angelo, grazia, additional, Simeone, Ester, additional, Festino, Lucia, additional, Vanella, Vito, additional, Trojaniello, Claudia, additional, Vitale, Maria Grazia, additional, Tafuto, Salvatore, additional, Caracò, Corrado, additional, Anniciello, Anna Maria, additional, Normanno, Nicola, additional, Bonito, Maurizio Di, additional, Warren, Sarah, additional, and Ascierto, Paolo, additional

Published
2021
Full Text
View/download PDF

49. Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

Author

Madonna, Gabriele, primary, Masucci, Giuseppe V., additional, Capone, Mariaelena, additional, Mallardo, Domenico, additional, Grimaldi, Antonio Maria, additional, Simeone, Ester, additional, Vanella, Vito, additional, Festino, Lucia, additional, Palla, Marco, additional, Scarpato, Luigi, additional, Tuffanelli, Marilena, additional, D'angelo, Grazia, additional, Villabona, Lisa, additional, Krakowski, Isabelle, additional, Eriksson, Hanna, additional, Simao, Felipe, additional, Lewensohn, Rolf, additional, and Ascierto, Paolo Antonio, additional

Published
2021
Full Text
View/download PDF

50. Additional file 1 of A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

Author

Simeone, Ester, Scognamiglio, Giosuè, Mariaelena Capone, Giannarelli, Diana, Grimaldi, Antonio M., Mallardo, Domenico, Madonna, Gabriele, Curvietto, Marcello, Esposito, Assunta, Sandomenico, Fabio, Sabbatino, Francesco, Bayless, Nicholas L., Warren, Sarah, SuFey Ong, Botti, Gerardo, Flaherty, Keith T., Soldano Ferrone, and Ascierto, Paolo A.

Abstract

Additional file 1: Table S1. HLA-A and HLA-B,C expression on melanoma cells in pre- and post-treatment biopsies. Abbreviation:% = percentage; Int = Intensity; Loc= localization.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results